MAPT and Alzheimer disease: Imaging of AD biomarkers is accomplished using amyloid positron emission tomography (PET) for Aβ, tau-PET for NFTs, and 18F-fluoro-deoxyglucose (FDG) PET or magnetic resonance imaging (MRI) for neurodegeneration5.